1. Adamson, U., Aparisi, T., Broström, L.-Å., Cantell, K., Einhorn, S., Hall, K., Ingimarsson, S., Nilsonne, U., Strander, H., and Söderberg, G.: Interferon treatment of human osteosarcoma. Pontificiae Acad. Scient. Scripta Varia 43, 383, 1979a.
2. Adamson, U., Aparisi, T., Broström, L.-Å., Cantell, K., Einhorn, S., Hall, K., Ingimarsson, S., Nilsonne, U., Strander, H., and Söderberg, G.: Adjuvant interferon treatment of human osteosarcoma. In, Recent Results in Cancer Research. Eds.: G. Bonnadonna, G. Mathé and S.E. Salmon. Springer-Verlag, Berlin/Heidelberg, 68, 40, 1979b.
3. Aparisi, T., Strander, H., Broström, L.-Å., and Nilsonne, U.: Experience avec l’interferon dans le traitement de l’osteosarcome. Proc. of the Journées Annuelle de Chirurgie Orthopedique. Ed.: J. Duparc, 1981. (In press)
4. Ban, S., Yamagiwa, T., Yanagawa, T., Sakakida, K., Ito, H., Murakami, K., Matsuo, A., Imanishi, J., and Kishida, T.: Effect of human leukocyte interferon on metastatic lung tumor of osteosarcoma and primary lung cancer. In, The Clinical Potential of Interferon. Eds.: R. Kono and J. Vilćek. University of Tokyo Press, pp 223, 1982.
5. Berthold, W., Grazia-Masucci, M.-G., Klein, E., and Strander, H.: Interferon treatment elevates the cytotoxic potential of lymphocytes and thereby increases the frequency of functional killer cells. Human Lymphocyte Differentiation 1, 1, 1981.